These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33342929)

  • 21. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island.
    Dubernet A; Larsen K; Masse L; Allyn J; Foch E; Bruneau L; Maillot A; Lagrange-Xelot M; Thomas V; Jaffar-Bandjee MC; Gauzere L; Raffray L; Borsu K; Dibernardo S; Renaud S; André M; Moreau D; Jabot J; Coolen-Allou N; Allou N
    J Glob Antimicrob Resist; 2020 Dec; 23():1-3. PubMed ID: 32828896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
    Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
    JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
    Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
    Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
    Lagier JC; Million M; Gautret P; Colson P; Cortaredona S; Giraud-Gatineau A; Honoré S; Gaubert JY; Fournier PE; Tissot-Dupont H; Chabrière E; Stein A; Deharo JC; Fenollar F; Rolain JM; Obadia Y; Jacquier A; La Scola B; Brouqui P; Drancourt M; Parola P; Raoult D;
    Travel Med Infect Dis; 2020; 36():101791. PubMed ID: 32593867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
    Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
    Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
    Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
    Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
    Thémans P; Belkhir L; Dauby N; Yombi JC; De Greef J; Delongie KA; Vandeputte M; Nasreddine R; Wittebole X; Wuillaume F; Lescrainier C; Verlinden V; Kiridis S; Dogné JM; Hamdani J; Wallemacq P; Musuamba FT
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):703-713. PubMed ID: 32968954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.
    Mallat J; Hamed F; Balkis M; Mohamed MA; Mooty M; Malik A; Nusair A; Bonilla MF
    Medicine (Baltimore); 2020 Dec; 99(52):e23720. PubMed ID: 33350752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
    Bhandari S; Singh A; Sharma R; Rankawat G; Banerjee S; Gupta V; Dube A; Kakkar S; Sharma S; Keswani P; Agrawal A; Tak A; Nawal CL
    J Assoc Physicians India; 2020 Jun; 68(6):13-19. PubMed ID: 32610873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
    Tang W; Cao Z; Han M; Wang Z; Chen J; Sun W; Wu Y; Xiao W; Liu S; Chen E; Chen W; Wang X; Yang J; Lin J; Zhao Q; Yan Y; Xie Z; Li D; Yang Y; Liu L; Qu J; Ning G; Shi G; Xie Q
    BMJ; 2020 May; 369():m1849. PubMed ID: 32409561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
    Réa-Neto Á; Bernardelli RS; Câmara BMD; Reese FB; Queiroga MVO; Oliveira MC
    Sci Rep; 2021 Apr; 11(1):9023. PubMed ID: 33907251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.
    Akram J; Azhar S; Shahzad M; Latif W; Khan KS
    Trials; 2020 Aug; 21(1):702. PubMed ID: 32771032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
    Chen CP; Lin YC; Chen TC; Tseng TY; Wong HL; Kuo CY; Lin WP; Huang SR; Wang WY; Liao JH; Liao CS; Hung YP; Lin TH; Chang TY; Hsiao CF; Huang YW; Chung WS; Cheng CY; Cheng SH;
    PLoS One; 2020; 15(12):e0242763. PubMed ID: 33264337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
    Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E
    J Glob Antimicrob Resist; 2020 Sep; 22():842-844. PubMed ID: 32763357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.